Former FDA Research Chemist, Ron Sekura B.S., M.S., PhD., Joins MusclePharm Board of Directors
October 21 2010 - 9:30AM
MusclePharm® Corporation (OTCBB:MSLP), one of the
fastest growing nutritional supplement company with a proprietary
formulation used in its portfolio of performance products,
announced today that Ron Sekura, B.S., M.S., PhD., will join
MusclePharm board of directors as its Director of Therapeutic
Research.
Dr. Sekura will be assisting in the development of the Company's
therapeutic indication and application for patients with HIV
experiencing catabolic cachexia.
Dr. Sekura commented, "I am very pleased to join the board of
MusclePharm as it expands into the field of therapeutic nutritional
supplementation for the application of HIV disease. Catabolic
cashexia is a wasting condition that is physically devastating and
extremely costly to treat. There has not been a great deal of
successful response with the current therapeutic options but I
believe Musclepharm is properly focusing on solving this
condition."
Ron Sekura is currently President of VivoNex LLC and
Biotechnology Assessment Services, Inc. Dr. Sekura is the former
Chief of the Pharmaceutical and Regulatory Affairs Branch of the
Division of AIDS at The National Institute of Allergy and
Infectious Diseases (NIAID) of the National Institute of Health
(NIH), as well as a former Research Chemist at The National
Institute of Child Health and Human Development (NICHD) at the NIH
and the Center for Biologics Evaluation and Research (CBER). He
received his Bachelor of Science and Master of Science in
Biochemistry degrees at Pennsylvania State University and his PhD
at Cornell University. Dr. Sekura is the author of over sixty
scientific publications.
"We are thrilled to have Dr. Sekura join our Board of Directors.
We believe Dr. Sekura's expertise at the FDA and NIAID, as well as
his research and work at VivoNex regarding HIV drug adherence, will
assist in our endeavor to provide our therapeutic nutritional
supplementation, Re-con, to people with HIV experiencing
involuntary weight loss, catabolic cachexia and nutrient
deficiencies," stated MusclePharm President, Cory Gregory.
MusclePharm is presently preparing their application for Recon
to be added to the Medicaid formulary, beginning in New York State
for people diagnosed with HIV and AIDS as well as nation-wide
Veterans Administration therapeutic formularies. In addition,
MusclePharm is exploring the distribution of MusclePharm products,
such as Recon, to people living with HIV in developing nations thru
The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The
Presidents Emergency Plan for AIDS Relief (PEPFAR)."
MusclePharm's Recon Nutritional Supplement contains important
amino acids, which assists in reaching the higher levels of
nutrition required for people living with HIV. It is easily
digestible, helps the absorption of amino acids and proteins. Recon
contains essential minerals, digestive enzymes, Glutamine and other
metabolic agents that maximize recovery, protein synthesis and
endurance.
About MusclePharm Corporation
Headquartered in Denver, Colorado, MusclePharm is a rapidly
expanding healthy life-style company that develops and
manufacturers a full line of NSF and scientifically approved,
nutritional supplements that are 100% free of any banned
substances. Based on years of research, MusclePharm products are
created through an advanced six-stage research protocol involving
the expertise of top nutritional scientists and field tested by
more than 100 elite professional athletes from various sports
including the NFL, MMA, and MLB. The Company's propriety and award
winning products address all categories of an active lifestyle
including muscle building, weight loss, and maintaining general
fitness through a daily nutritional supplement regimen. MusclePharm
is sold in over 120 countries and available in over 5,000 US retail
outlets that include GNC, and Vitamin Shoppe, as well as over 100
online stores, including bodybuilding.com, Amazon and
Vitacost.com. For more information, please visit
www.musclepharm.com.
Forward-looking Statements
MusclePharm Corporation believes the information set forth in
this Press Release may include "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Act of 1934. Certain factors that could cause
results to differ materially from those projected in the
forward-looking statements are set forth in "Risk Factors" in
Item2.02 of the Company's Form 8-K dated February 18, 2010, which
has been filed with the Securities and Exchange Commission.
CONTACT: ICR
Investor Relations Contact:
John Mills, Senior Managing Director
310-954-1105
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From May 2024 to Jun 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jun 2023 to Jun 2024